Latest News for: neuroblastoma

Edit

Treatment of childhood neuroblastoma target of research project (University of Windsor)

Public Technologies 24 Jan 2025
... led research project will explore ways to improve treatment outcomes for the extracranial childhood cancer neuroblastoma.
Edit

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire 07 Jan 2025
7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB).
Edit

Better chances for chemotherapy in neuroblastoma

Science Daily 12 Nov 2024
Blocking the METTL3 protein can increase sensitivity to chemotherapy in neuroblastoma, according to new research. The study shows how specific RNA modifications affect gene expression in the early development of neuroblastoma ... .
Edit

Kendall's Pet Scan Results (Neuroblastoma)

Rumble 28 Oct 2024
Go to the source via the article link to view the video or click the video icon ....
Edit

How has chemo effected Kendall's body? Testing for Stem Cell Transplant (Neuroblastoma)

Rumble 27 Oct 2024
Go to the source via the article link to view the video or click the video icon ....
Edit

US FDA Grants RPD Designation To Senhwa Biosciences Silmitasertib For Pediatric Neuroblastoma

MENA FN 13 Sep 2024
(MENAFN - PR Newswire). TAIPEI and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx. 6492), a new drug development company focusing on first-in-class therapeutics for ... .
Edit

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference ...

Nasdaq Globe Newswire 06 Sep 2024
... today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma.
Edit

RedHill’s Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Pharmiweb 27 Aug 2024
Food and Drug Administration (FDA) has granted orphan-drug designation to opaganib for treatment of neuroblastoma, a type of childhood cancer that develops from immature nerve cells and accounts for 15% of all pediatric cancer-related deaths.
Edit

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Victoria Advocate 26 Aug 2024
Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric cancer-related deaths, ....
Edit

Neuroblastoma Drugs Business Research Report 2023-2030: Evolving Landscape of Combination Therapies Expands Addressable Market Opportunities

Nasdaq Globe Newswire 21 Aug 2024
21, 2024 (GLOBE NEWSWIRE) -- The "Neuroblastoma Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Edit

Children's Hospital of Philadelphia Researchers Reveal New Hope for Chemotherapy-Resistant Neuroblastoma Patients

Fort Wayne Journal Gazette 16 Aug 2024
Study is the first to identify malignant cells responsible for relapse in high-risk neuroblastoma ... .
Edit

Children’s Hospital of Philadelphia Researchers Reveal New Hope for Chemotherapy-Resistant Neuroblastoma Patients (Children’s Hospital of Philadelphia)

Public Technologies 14 Aug 2024
The study marks the first time that researchers identified malignant cells responsible for relapse in neuroblastoma and offers insights for potential new therapeutic targets.
Edit

Essential Pharma and AGC Biologics Partner on late phase clinical manufacturing of immunotherapy candidate for the treatment of high risk neuroblastoma (AGC Biologics Inc)

Public Technologies 17 Jun 2024
Essential Pharma Partners with AGC Biologics to Accelerate Development and Production of Promising Neuroblastoma Therapy Hu14.18 ... Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy.
Edit

Neuroblastoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight ...

GetNews 08 May 2024
Some of the key takeaways from the Neuroblastoma Pipeline Report. ... Neuroblastoma Overview ... Neuroblastoma Molecule Type ... Neuroblastoma current marketed and Neuroblastoma emerging therapies ... Neuroblastoma market drivers and Neuroblastoma market barriers.

Most Viewed

×